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Case presentations
Patient 1. A 55-year-old black woman was referred for evaluation of an
elevated serum creatinine concentration; the serum creatinine level had
been 1.2 mg/dl 4 years prior and 1.8 mg/dl 8 months prior to referral. At
the initial evaluation, the serum creatinine was 4.6 mg/dl. The patient had
a four-year histoiy of non-insulin-dependent diabetes mellitus. She had
been treated for glaucoma and retinal hemorrhages secondary to diabetic
retinopathy. She also had had severe, poorly controlled hypertension for at
least four years. Hypercholesterolemia had been noted, but she had
suffered no major cardiovascular events. At the time of the initial
evaluation, the patient was taking nifedipine, indapamide, simvastatin, and
glyburide.
Physical examination revealed a blood pressure of 204/86 mm Hg,
scarred retinae with evidence of prior laser photocoagulation, vitiligo of
the hands and back, and the absence of vascular bruits. Radiologic
examination showed slight renal asymmetry by ultrasound (right kidney
11.3 cm, left 12.7 cm) and symmetric but diminished renal perfusion by
nuclear scan.
Laboratory testing was negative for ANA, ANCA, and rheumatoid
factors; serum protein electrophoresis and C3, C4, and CH5O levels were
normal. The 24-hour urine protein excretion was 6.8 g; serum creatinine,
4.6 mg/dl; and creatinine clearance, 14 cc/mm. A presumptive diagnosis of
diabetic retinopathy was made, but when the serum creatinine rose to 5.6
mg/dl four weeks later, renal biopsy was carried Out because of the rapid
progression and atypical history. The biopsy confirmed advanced diabetic
glomerulosclerosis; captopril administration was started at that time.
Table I details the course of her renal function. Dialysis access was
placed two months after the biopsy, when the serum creatinine was 7.0
mg/dl; 14 months later she still had not required dialysis.
Patient 2. A 35-year-old white woman was referred for evaluation of
proteinuria and azotemia. She reported a 20-year history of insulin-
dependent diabetes mellitus, complicated by gastroparesis, proliferative
retinopathy, peripheral neuropathy with orthostatic hypotension, and a
two-year history of hypertension. Medications included diltiazem, insulin,
furosemide, and metoelopramide. On examination, her blood pressure
was 160/90 mm Hg supine and 130/80 mm Hg seated. Advanced retinop-
athy was present. No vascular bruits, heart murmurs, or skin rashes were
noted. She had 3+ pedal edema.
Laboratory evaluation showed a serum creatinine of 3.0 mg/dl; potas-
sium, 5.3 mEq/liter; 24-hour urinary protein excretion, 6 g; and a
creatinine clearance of 28 cc/mm. The ANA, ANCA, serum protein
electrophoresis, cortisol, and complement levels were negative or normal.
Renal imaging studies were unremarkable. A clinical diagnosis of diabetic
nephropathy was made, and captopril was started at a dose of 12.5 mg
orally every 12 hours.
Subsequent laboratory tests revealed a potassium of 6.2 mEq/liter and
a serum ereatinine of 3.2 mg/dl; the patient reported severe orthostatic
symptoms. Dietary restriction of potassium and the addition of fludrocor-
tisone, 0.1 mg orally every 12 hours, lowered the serum potassium level to
5.4 mEq/liter, but she was unable to tolerate higher doses of captopril
because of orthostasis. The serum creatinine increased to 5.6 mg/dl and
captopril was discontinued; her renal function did not improve. The
patient progressed to end-stage renal disease 12 months after initial
presentation.
Discussion
DR. JEKuNI IcHIKAwA (Professor of Pediatrics and Head, Division
of Pediatric Nephrology, Vanderbilt University Medical Center,
Nashville, Tennessee): It is widely recognized that angiotensin-
converting-enzyme (ACE) inhibitors can retard the progression of
renal failure in at least two common renal diseases, namely,
diabetic nephropathy and IgA nephropathy, in a manner indepen-
dent of their blood-pressure-lowering effect [1, 2]. Worldwide,
ACE inhibitors have become the second class of drugs to be
verified by multicenter clinical trial studies as an effective thera-
peutic intervention for progressive renal failure.1 Diabetic ne-
phropathy and IgA nephropathy are the most common primary
diseases leading to chronic renal failure. Together, they account
for more than one-half the patient population currently receiving
renal replacement therapy in the U.S. and other industrial na-
tions. Characteristically, the mode of progression in these diseases
is slow. Assessment of the efficacy of ACE inhibitors in other,
more rapidly progressive diseases, has been difficult at least in part
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An oral adsorbent (Kremezin®) has recently become available in
Japan as an over-the-counter "renal insufficiency drug." The efficacy of
this adsorbent has been verified in animal studies [3] and in prospective,
double-blind, randomized multicenter clinical trials [41.
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Table 1. Serum creatinine values
Month 1 8 9 10 12 13 14 16 17 19 22
(mg!dl) 1.8 4.6
(initial
evaluation)
5.6 6.8 7.0 6.6 6.7 6.7 6.9 5.6 6.6
because of the smaller number of patients. Even in IgA nephrop-
athy, when loss of renal function is rapidly progressive, the
pathophysiologic contribution of angiotensin (Ang II) to the
progression of disease appears relatively small [5]. Taken to-
gether, these observations suggest that the role of Ang II is most
evident in the more slowly progressive disorders.
Not all patients with renal failure from IgA nephropathy or
diabetic nephropathy benefit from treatment with ACE inhibitors.
Recent genotyping studies indicate that the pathophysiologic role
of Ang II varies according to the specific genotype within the
components of the renin-angiotensin system (RAS) [6—8]. Among
these genes, variance in the ACE gene has been closely linked to
the progression of some renal diseases. Therefore, the patient's
genetic burden, which influences variability in the pathogenetic
contribution of Ang II, might underlie the variability in the
efficacy of the ACE inhibitor that has been seen in clinical trials.
Indeed, one recent study in Japanese patients has demonstrated a
significant correlation between a variant in the ACE gene and the
responsiveness to ACE inhibition in patients with IgA nephrop-
athy [7].
Ang II receptor antagonists
Recently, a new class of angiotensin inhibitor—angiotensin
type-i receptor antagonist (AT1a)—has become available as
another long-acting oral antihypertensive therapy. Given the
differences in pharmacokinetics between AT1a and ACE inhibi-
tors, their effects on renal structure and function also might differ
considerably. Thus, the angiotensin converting enzyme is the
identical enzyme involved in the degradation of bradykinin (kini-
nase II), such that ACE inhibition is accompanied by activation of
bradykinin. The AT1 receptor antagonist does not activate bra-
dykinin, however. Second, Ang Ii is under negative feedback
control at the level of the juxtaglomular apparatus (JGA). Acti-
vation of the AT1 receptor on JGA cells suppresses renin release
from these cells and lessens the level of angiotensin. When the
AT1 receptor is inhibited by the antagonist, therefore, the syn-
thesis and release of renin and angiotensin are activated. The
short- and long-term consequences of this uncontrolled activation
of renin and angiotensin are currently unclear as the function of
non-AT1 receptors known to exist is not well understood. Thus,
while AT1a may specifically inhibit the AT1-mediated Ang II
actions, AT1a also might augment other unknown actions of Ang
II. In contrast, ACE inhibitors can inhibit all of the Ang II actions,
although the inhibition may be incomplete if other enzyme(s) can
catalyze the synthesis of Ang II as suggested recently.
Experimental animal data reveal differences in the acute hemo-
dynamic effect on glomerular filtration rate (GFR) between ACE
inhibitors and AT1a. AT1a appears superior over ACE inhibitors
in that it causes less of a reduction in GFR, a clearly undesirable
side effect that commonly occurs at the onset of ACE inhibitor
administration. Chronically, however, AT1a might be less reno-
protective in terms of preserving GFR and structure; the salutary
effect of ACE inhibition on the renal tissue might in part be
mediated by non-type-i receptor mechanisms. It is important,
then, that direct clinical comparison studies between these two
classes of agents be performed to evaluate their capacity to retard
the progression of renal failure.
In preparing this presentation, I conducted a small-scale survey
among practicing internists and nephrologists to ascertain their
pattern of prescribing antihypertensive drugs for patients with
chronic renal disease. The results were collected from 20 practic-
ing nephrologists, mostly in private practice settings, in a form of
multiple choice survey. The survey consisted of four questions
regarding reasons for choosing captopril versus enalapril or an
ACE inhibitor versus a receptor antagonist. When queried on
their choice of captopril over enalapril, 50% cited economic
reasons. Of the remaining 50%, one-half chose medical reasons
that have not been established in humans, that is, a greater
renoprotective or a greater cardioprotective effect. When asked
about their choice of a receptor antagonist over an ACE inhibitor,
30% selected the former, primarily to acquire experience with the
new drug. The results indicate that the choice of medication, for
the most part, is not based on medical or clinically proven reasons.
Given the current rapid shift in the medical care environment
toward a "cost-controlled care" system, acquisition of valid clini-
cal data is essential for physicians to be able to prescribe the best
medications for their patients. This fact further emphasizes the
need for clinical comparison of ACE inhibitors and receptor
antagonists.
Several studies have shown that GFR, or a reciprocal of serum
creatinine concentration, declines linearly over time in a predict-
able manner in patients with progressive renal diseases (thin solid
line, Fig. 1), although the rate of decline or the gradient of the
slope varies among patients [9]. In multicenter and independent
studies in patients with diabetic nephropathy or IgA nephropathy,
administration of ACE inhibitors was effective in attenuating this
progressive decline in GFR [1, 2]. The results showed that ACE
inhibitors reduce the gradient of the GFR slope (thick solid line,
Fig. 1). As I noted earlier, administration of an ACE inhibitor
typically induces an abrupt, albeit modest, fall in GFR initially
(Fig. 1), so that it requires months to demonstrate the beneficial
overall effect on GFR. As this initial fall in GFR is acute,
self-limiting, and readily reversible after withdrawal of the ACE
inhibitor [10], this phenomenon is believed to be hemodynamic in
nature. In contrast is the subsequent salutary effect of ACE
inhibition on GFR, which is exhibited over an extended period in
a steady and predictable manner, and hence in all likelihood
reflects the structure-preserving effect of ACE inhibition on the
kidney.
Using an experimental model, we simulated the reduction in
GFR that often occurs shortly after the onset of ACE inhibitor
administration [11]. The intravenous infusion of an ACE inhibitor
significantly reduced GFR; administration of ATia increased
GFR, although both induced comparable renal vasodilation and
increases in glomerular plasma flow. Micropuncture analysis of
glomerular hemodynamics revealed that the difference between
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Fig. 1. The predicted effect of the A Ti antagonist in comparison with the
effect of an ACE inhibitor on GFR in chronic progressive renal diseases. The
thin solid line represents the natural course of decline in GFR without
treatment, and the thick solid line represents the GFR course during ACE
inhibitor administration. The thick dotted lines represent the two extreme
scenarios for GFR during AT1 antagonist administration. The diagram is
based on the observations both in humans and experimental animals that
(1) in typical chronic progressive renal diseases, GFR declines as a linear
function of time, and (2) ACE inhibitor administration causes a mild fall
in GFR initially, (3) but subsequently the rate of fall in GFR is lessened
rather than otherwise. (4) In animals, AT1 antagonist, when compared to
ACE inhibitor, did not cause an acute fall in GFR.
the two drugs' effect on GFR is attributed to the ACE inhibitor's
greater ability to dilate the efferent arteriole, thus causing a
profound fall in glomerular capillary pressure. As I said earlier,
the ACE inhibitor inactivates kininase II, a kinin-degrading
enzyme that would result in an accumulation of bradykinin. This
phenomenon is of particular relevance since an in-vitro study,
using isolated rabbit renal interlobular, efferent, and afferent
arteriolar preparations, demonstrated that bradykinin causes
marked vasodilation only in the efferent arteriole [121. With the
use of a specific bradykinin receptor antagonist, we further
demonstrated that the uniquely potent efferent vasodilatory effect
of ACE inhibition in rats is attributed to the ACE inhibitor's
ability to augment bradykinin. Although it remains to be estab-
lished that the initial fall in GFR that occurs with ACE inhibition
in patients with progressive renal disease is also attributed to
bradykinin, some preliminary data in humans indicate that ATIa
also might differ from ACE inhibitors in that they do not cause an
initial fall in GFR. A study reported recently in abstract form has
shown that GFR remained unaffected during administration of
AT1a over approximately 12 weeks in doses sufficient to reduce
systemic blood pressure by approximately 12 mm Hg [13]. This
study thus established the short-term "safety" of using ATIa in
patients with modest chronic renal insufficiency. Gansevoort et a!
obtained similar results in a smaller patient population [141.
Aside from observations regarding the early effect of AT1a on
GFR, no human data have been collected that would indicate a
renoprotective effect of AT1a in chronic progressive renal dis-
eases. What information have we gained from the currently
available animal data?
Thus far, two animal models of progressive renal diseases have
compared the effectiveness of ACE inhibitors and AT1a [15—17].
In those in-vivo studies, these two agents were comparably
effective at the dose tested in protecting kidneys from progressive
structural damage. Two important caveats need to be stated. First,
a considerable gap exists between animal and human situations
with regard to the efficacy of ACE inhibitors. Thus, whereas in
numerous animal studies, ACE inhibitors have completely abro-
gated the progression of renal failure, the effect of ACE inhibitors
in humans has been found to be variable and partial at best, and
only to postpone the requirement for dialysis. Second, the animal
models used in these studies are rapidly progressive in nature;
hence they might not have desirably close relevance to most
chronic renal diseases in humans [18]. The therapeutic efficacy of
ACE inhibition in humans thus far has been demonstrated only in
slowly progressive diseases, that is, diabetic and IgA nephropa-
thies [1, 2]. Therefore, the animal models (with rapidly progres-
sive renal failure) used thus far might be too short-lived to
precisely predict the renoprotective abilities of ACE inhibitors
versus ATIa in humans. In-vivo and in-vitro studies already have
identified a few specific differences in biologic activity between
these two classes of agents that might affect the renoprotective
capacity of these agents.
Glomeru/ar hemodynamics. Studies in animal models have
shown that the salutary effect of ACE inhibition on glomerular
structure is closely associated with its potent ability to lower
glomerular pressure [19—21]. Although more indirectly studied,
similar phenomena are seen in humans. Thus, among patients
with a progressive decline in renal function who benefited from
ACE inhibitor administration, the initial fall in GFR (which is
presumed to result from a fall in glomerular capillary pressure)
was closely associated with, and hence appeared to be a prereq-
uisite for, the subsequent attenuation of the decline in GFR. In
acute and chronic settings, AT1a was substantially less potent than
the ACE inhibitor in lowering glomerular pressure in the kidney
[11, 15], although in other instances the drugs were comparable
[16]. In parallel with these experimental findings, the administra-
tion of AT1a in patients with declining renal function did not
significantly reduce GFR, a finding typically associated with
administration of ACE inhibitors [13, 14]. If the fall in glomerular
pressure and GFR is indeed critically important for the renopro-
tective action of ACE inhibitors (as some speculate), one might
predict that attenuation of the progressive fall in GFR that can be
achieved by AT1a would be substantially limited (Fig. 1). Thus,
clinical trials (comparing ACE inhibitors and AT1a) are needed
to assess the long-debated significance of the glomerular-pres-
sure-lowering effect of ACE inhibitors as a mechanism of the
renoprotection.
Extracellular matriK degradation. Accumulation of extracellular
matrix (ECM) in the mesangial region and collapse of the
glomerular capillary wall are the hallmark of glomerulosclerosis.
Administration of an ACE inhibitor downregulates ECM expres-
sion in renal disease models. Thus, in diabetic rats, enalapril
attenuates the otherwise abnormally upregulated mRNA for
al(IV) collagen, laminin Ri, B2, al(I), and a2(IlI) [22]. In-vitro
studies have shown that Ang II can affect the production and
degradation of ECM independently of the systemic milieu, for
example, hemodynamic, hormonal, or lipid environments [23].
In-vivo transfection of the renin and angiotensin genes with
liposomes induced ECM expansion and type-I and -III collagen
expression in glomeruli [24]. Extracellular matrix can be accumu-
lated not only by upregulation of its synthesis but also by
downregulation of its degradation. The importance of this degra-
dation mechanism for the development of glomeruloselerosis is
Ti me
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attested to by experimental demonstrations that, when accumula-
tion of ECM is markedly attenuated, even established glomeru-
loscierosis can be reversed [25, 26].
Extracellular matrix proteins are degraded by a number of
proteinases. As a regulator of this system, plasminogen activator
inhibitor-i (PAl-i) plays a pivotal role. The importance of PAT-I
in ECM generation in the kidney was shown by a study in which
administration of PAl-i-neutralizing antibodies to cultured mes-
angial cells resulted in a severalfold increase in the amount of
ECM [27]. Moreover, normal murine kidneys contain a very low
level of PAT-I, whereas in MRL/lpr mice, a mouse model of lupus
nephritis, PAl-i is expressed in endothelial cells, parietal epithe-
Hal cells, tubular epithelial cells, and infiltrating mononuclear cells
in the tubulointerstitiuni [28]. These observations collectively
indicate that activation of PAl is an important component of the
renal tissue accumulation of extracellular matrix.
The degradation of mcsangial ECM can be stimulated by ACE
inhibitors via multiple mechanisms. Thus, ACE inhibition can
suppress angiotensin's capacity to induce PAl, which is transduced
by Ang 11 type-I [29] and non-type-i receptor [30]-depcndent
pathways (Fig. 2). Furthermore, bradykinin, the degradation of
which can be downregulated by ACE inhibition, can induce
plasminogen activator release (Fig. 2). In this regard, ATIa lacks
two of the three mechanistic channels for plasminogen activation,
namely, type-4 receptor and bradykinin [301. If the ACE inhibi-
tor's ability to activate matrix degradation is sufficient to prevent
matrix expansion, sclerosis, and fibrosis, and if the type-4 receptor
and bradykinin mechanisms are important components of the
ACE inhibitor's ability to stimulate plasminogen, or more pre-
cisely matrix degradation, AT1a would he expected to be less
effective in attenuating the progressive sclerosing and fibrosing
processes.
Proteinuria. Proteinuria of some magnitude precedes the pro-
gressive destruction of renal architecture in virtually all renal
diseases. It is natural, therefore, that proteinuria has been alleged
to be causally linked to renal damage. Gansevoort et a! found that,
among a diabetic patient population given ACE inhibitors, a
strong correlation existed between the magnitude of suppression
of proteinuria achieved shortly after initiation of ACE inhibition
and the degree of attenuation of progressive loss of GFR [311.
The mechanism proposed involves proteinuria-induced activation
of the complement cascade [32, 33], which leads to inflammatory
interstitial changes. Besides the possible direct effects on the
tubulointerstitium, whenever proteinuria is associated with hy-
poproteinemia, proteinuria can indirectly, by affecting lipid me-
tabolism, promote progression of renal disease. Both in animal
models and in patients with nephrotic syndrome, ACE inhibition
reduces the plasma lipid level [34, 35]. The renal protective effect
of ACE inhibition in patients with massive proteinuria therefore
might be mediated in part by its lipid-lowering capacity.
In an experimental animal model of progressive loss of renal
function and severe proteinuria [15], ACE inhibitors and AT1a
differed markedly in their ability to dampen proteinuria; acute
treatment with an ACE inhibitor but not ATIa promptly de-
creased proteinuria. Notably, the acute antiproteinuric effect of
ACE inhibition was significantly dampened by a specific bradyki-
nm receptor antagonist. Thus, this difference in acute antiprotein-
uric effects between ACE inhibition and ATIa likely is due to the
ACE inhibitor's capacity to augment bradykinin. The ACE-
inhibition-induced reduction in proteinuria might be related to a
reduction in the abnormally large number of non-selective pores
existing on the glomerular capillary wall of diseased kidneys as a
consequence of normalization of the abnormally high glomerular
pressure. Although the pathophysiologic effect of proteinuria on
the progression of renal disease per se is still uncertain, the results
to date suggest a possible therapeutic advantage of ACE inhibi-
tors over AT1a in reducing proteinuria.
A recent study by Yoshida and colleagues demonstrated vari-
ability in the responsiveness of proteinuria to ACE inhibitors
among patients with progressive IgA nephropathy. Specifically,
ACE inhibitors attentuated proteinuria only in patients with IgA
nephropathy who carry a specific pattern of polymorphism in the
ACE gene [7]. Notably, this particular gene polymorphism previ-
ously has been associated with elevated levels of serum ACE [36].
It is conceivable, then, that the reduction in proteinuria following
ACE inhibition identifies a specific group of patients in whom the
renin-angiotensin system is activated. Thus, ATIa is expected to
attenuate progression as effectively as do ACE inhbitors only if
the discrepancy in the antiproteinuric effect of the ACE inhibitor
and ATI a is pathophysiologically insignificant.
Cellular infiltration. A small population of resident macro-
phages is believed to be present within normal glomeruli. In many
forms of human glomcrulonephritis, macrophages accumulate not
only within the glomerulus but also in the interstitium. The
importance of macrophages in the initiation and progression of
renal injury has been demonstrated in studies in which macro-
phage deletion by X-irradiation or anti-macrophage serum atten-
uated glomerular and tubulointerstitial injuries [37-39].
In experimental models of obstructive nephropathy [40], infil-
tration of macrophages and monocytes occurs at stages prior to
Angiotensin I
Bradykinin
Plasminogen
Plasmin
Latent metalloproteinases
Active metalloproteinases
ECM degradation
Fig. 2. Mechanism of the effect of ACE inhibitor on the degradation of
extracellular matrix (ECM), involving plasminogen activators and plasmino-
gen activator inhibitors (PA!).
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Reduction in blood pressure Reduction in blood pressure
Fig. 3. Involvement of AT2 receptor in the blood- pressure-lowering effect of AT] antagonists and ACE inhibitors. The diagrams indicate that when a
comparable reduction in blood pressure is achieved with an ATI antagonist and an ACE inhibitor, the status of the AT1 receptor is more profoundly
inhibited with the ACE inhibitor than with the AT1 antagonist.
the onset of typical progressive fibrotic changes in the interstitium,
and this initial cellular infiltration likely is a key event leading to
subsequent scarring. Morrissey et at found ACE inhibitors more
effective than AT1a in attenuating this macrophage/monocyte
infiltration, although activation of macrophages is believed to be
mediated by the type-i receptor on the cell surface [411. Given
that cellular infiltration occurs through a dynamic interplay be-
tween macrophages/monocytes and the resident cells, most nota-
bly endothelial cells, the observed difference should be attributed
to ACE inhibitors' unique properties such as upregulating brady-
kinin, which may have the ability to downregulate the release of
chemotactic factors from endothelial cells. In this preliminary
study, AT1a and the ACE inhibitor equally protected the kidney
from interstitial fibrosis, however. Further studies are required to
establish whether the different effect of the two classes of drugs on
macrophage infiltration has a significant impact on their capacity
to retard progression of renal diseases in humans.
Magnitude ofATi inhibition. The activity of the renin-angioten-
sin system is tightly controlled by a negative feedback mechanism.
That is, a high Ang II level suppresses release of renin by the JGA
cells through the AT1 receptor on those cells. Existence of this
negative feedback system dictates that AT1a administration up-
regulates angiotensin. This phenomenon raises a concern regard-
ing the consequence of upregulation of angiotensin, combined
with intact non-type-i receptor(s), particularly type-2 receptor(AT2), which is a scenario predicted by the pharmacologic
blockade of AT1. Recent genetic engineering, which has made it
possible to selectively knock out the type-2 receptor gene in mice,
has revealed that the role of the type-2 receptor includes trans-
duction of the blood-pressure-lowering effect of angiotensin [42].
This observation allows speculation that the reduction in blood
pressure induced by AT1a is attributed not only to an inhibition of
AT1 but also to an activation of AT2 as a result of a high ambient
level of Ang II acting on intact AT2 receptors (Fig. 3). In contrast,
both AT1 pressor activity and AT2 anti-pressor activity are
suppressed during ACE inhibitor administration because of at-
tenuation of ligand production. Collectively, therefore, for a given
degree of reduction in blood pressure, a lesser degree of AT1
inhibition is required by AT1a than by the ACE inhibitor. Thus,
even if the angiotensin-dependent processes of sclerosis and
fibrosis are channeled entirely through the AT1-dependent mech-
anism, ACE inhibitors might provide more renoprotection than
ATia, assuming that they are prescribed at doses resulting in
equivalent reduction in blood pressure. Thus, overall, AT1a lacks
several properties that could be important in the renoprotective
actions of ACE inhibitors.
Speculation and concerns
Results from experimental studies have led us to predict that
the data from clinical trials with AT1a follow a pattern between
the following two extreme scenarios. We have described that,
unlike ACE inhibitors, AT1a lacks the initial GFR-lowering effect
(Fig. 1). Thus, if ATia, despite all the already described reserva-
tions, can exert a structure-preserving effect similar to the ACE
inhibitors, ATia is expected to preserve GFR for a substantially
longer period than can the ACE inhibitor by having the slope of
GFR intercepting the X axis shift rightward toward that for ACE
inhibitor administration (Fig. 1). The other extreme is a scenario
in which a lack of profound hemodynamic and other effects
indeed might critically deprive AT1a of the ability to protect
kidneys, and result in a progressive decline in GFR that is much
faster than that seen with ACE inhibition (Fig. 1). Clinical trials
not only will provide valuable information regarding the optimal
modality for minimizing the progression of renal diseases, but
they also will identify mechanisms that are important for the
renoprotective effect of pharmacologic Ang II inhibition.
Figure 1 illustrates that the effect of an ACE inhibitor and
ATia on glomerular filtration rate comprises both hemodynamic
and structural effects. In fact, if these agents are comparable in
terms of structural preservation, as predicted by some experimen-
tal animal studies [15, 161, Figure 1 implies that ATIa might be
preferable over an ACE inhibitor, as the former will prolong the
AT1 antagonist
11 Removal of the feedback
suppression of renin
Inhibition of AT1
. synthesis/release by JGA
cells
'Ir
Reduction in blood pressure Increase in Ang II
Activation of AT2
ACE inhibitor
______
1
Decrease in Ang II
Inhibition of AT1 Inhibition of AT2
Reduction in blood pressure
e
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time that the patient's own kidneys will function. It is apparent
from Figure 1 that the value of GFR measured at any single point
fails to determine the relative potential benefit of these agents.
A recent study by Gansevoort et a! demonstrated a strong
correlation between the degree of reduction in proteinuria
achieved shortly after initiation of ACE inhibitor administration
and the degree of preservation achieved during a subsequent
long-term period [311. As I said earlier, human genotyping studies
revealed a strong correlation between the ACE gene genotype
versus the progression of renal failure [6—8], and the same
genotype versus the degree of reduction in proteinuria following
ACE inhibitor administration [7]. Thus, the antiproteinuric effect
of ACE inhibition that occurs shortly after administration of these
agents might identify the specific group of patients in which All is
pathophysiologically important, and in whom ACE inhibition will
preserve GFR. Nevertheless, because the early antiproteinuric
effect of ACE inhibition can primarily be hemodynamically me-
diated, and because the hemodynamic effects of ATIa and ACE
inhibitors are potentially markedly different, the degree of reduc-
tion in proteinuria alone cannot be taken as an index for their
structure-preserving effect in comparing these agents.2
Given the results from human studies that demonstrate a
variability in the responsiveness to ACE inhibitors, a variability
largely reflecting a specific genotype, it might be especially
important to assess the efficacy of these two agents in genotype-
matched groups of small patient populations. Studies conducted
thus far have failed to demonstrate a significant influence of
angiotensin-related genes other than ACE, for example, angio-
tensinogen and AT1 genes [44, 45], in the progression of renal
disease. Studies have shown that the ACE gene polymorphism
also determines the risk of cough, a side effect of ACE inhibitors
[46, 47]. The genotype for ACE that was found to respond well to
the antiproteinuric effect of ACE inhibition is the genotype least
likely to produce cough and angioneurotic edema. It is conceiv-
able that after genotyping identifies the specific group of patients
predicted to benefit from the renoprotective effect of ACE
inhibition, these patients might be found to be those least likely to
develop this and other ACE-inhibitor-induced adverse effects. For
the test to be meaningful, therefore, it is important that we
identify the specific group of patients who are likely to respond to
pharmacologic inhibition of Ang II.
Questions and answers
DR. NCoLAOS E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): Could you sum-
marizc the distribution and function of the AT2 receptor in the
kidney and whether its distribution or density might change in
renal disease?
DR. ICHIKAWA: A couple of groups have performed in-situ
hybridization studies [48, 49]. Angiotensin type-2 receptor within
2 An additional complication exists: it remains uncertain, in humans or
experimental animals, when the hemodynamically mediated antiprotein-
uric effect of the ACE inhibitor has achieved its maximum, and when its
structure-preserving effect is primarily responsible for the reduced pro-
teinuria [10, 43]. Even at the systemic circulatory level, the maximum
hemodynamic effect of antihypertensive medication requires vascular
restructuring, including the reversal of the hypertrophy of peripheral
resistance vessels, which requires an extended period of antihypertensive
therapy.
the kidney is demonstrable only during the embryonic stage and
not in the adult kidney. In adults, however, if you give angiotensin
AT2 antagonist, natriuresis occurs [50]. It is believed that AT2's
function is salt retaining. All of those in-vivo studies with receptor
antagonists were performed in whole animals, however. It is
therefore not known whether the antagonist acts within the kidney
or through the central nervous system, for example, by inhibiting
adrenergic outflow, for which AT2 is a very important regulator.
DR. MADIAS: I was very impressed by the results of the ACE
gene polymorphism in IgA patients you referred to. Is there any
information about this polymorphism in non-Asian populations?
Also, are there polymorphisms in other genes of the renin-
angiotensin system that might have relevance to the progression
of renal disease?
DR. IcI-HKAwA: I understand your interest. What the results
imply is that we might have to genotype patients before we give
angiotensin inhibitors. In the future, once we have identified all
pathogenetic factors for the particular disease, we can genotype
each patient for all those factors and then give the appropriate
medications. There are some ongoing studies on non-Asian
populations. One study shows essentially identical results in terms
of ACE gene polymorphism in IgA nephropathy [6]. Another
study in the US shows a similar tendency for the ACE gene
polymorphism to affect progression of IgA [451. A few studies also
have identified a significant correlation in another entity, that is,
diabetes, between ACE gene polymorphism and progression [51].
These conclusions appear very convincing. A diabetic patient with
proteinuria and DD polymorphism is certain to develop renal
failure well within 10 years—it's that type of very strong correla-
tion. Some of the studies on cardiac disease indicate that if one
has two specific features in terms of the polymorphism of renin-
angiotensin-system genes, the impact of these polymorphisms on
prognosis becomes exponential.
DR. JOHN T. HARRINGTON (Dean ad interim, Tufts University
School of Medicine, Boston, Massachusetts): Do you have data on
what percentage of normal individuals have DD, DI, or II? Do
you have similar information on a cohort of patients with poly-
cystic kidney disease, diabetes, or IgA?
DR. ICHIKAWA: In general, in terms of population, the distribu-
tion in American whites is 25% DD, 50% DI, and 25% II. In the
Asian population, it is 10% or 11% DD, and the rest is hetero-
zygote or II. Interestingly, in Japanese populations, some 30% of
IgA have DD, higher than the general population. It means that
there might be a substantial number of IgA patients within the
population who do not come to clinic because their manifestations
are minor. In the presence of DD, the disease may become overt
and the patients may seek medical attention and become a part of
the 30%. Studies have not been done on polycystic kidney disease.
DR. ANDREW S. KING (Division of Nephrology, New England
Medical Center): I have been impressed by the similarities of the
renal effects of AT1 receptor antagonists and ACE inhibitors. In
particular, I am referring to the work by Richard Lafayette and
Timothy Meyer [16], Sharon Anderson [48], and Andrea Remuzzi
[49], studies examining the effects of AT1 receptor blockade in the
streptozotocin-induced diabetes model and remmant kidney
model. Would you care to comment on those studies? We are
always confronted with the dilemma of determining the equiva-
lent dosage of two different classes; in these studies, dosages were
titrated to systemic blood pressure. My assessment of these
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studies is that the protective effect of ACE inhibitors was mostly
due to a reduction in angiotensin II.
DR. ICHIKAWA: In human studies, the course of progression is a
lot longer than that in animal situations. Freedman wrote that
animal studies are just too short to test some of the functions and
possible pathophysiologic mechanisms [18]. Today, I attempted to
present currently conflicting results in a balanced way. In this
regard, Dr. de Zeeuw's recent statements are particularly inter-
esting [14]. Clinical data generated by him and his colleagues
indicated that the AT1 antagonist is safe because it does not
reduce GFR. He also holds the view that ACE inhibitors'
renoprotective effect is closely associated with their ability to
acutely reduce GFR. Therefore, whether the AT1 antagonist's
lack of GFR-reducing effect in humans reflects its inability to
protect kidneys long-term awaits human studies.
DR. MADIAS: Considerable work indicates that ACE inhibitors
affect the porosity of glomerular membrane by reducing the
average diameter of the nonselective large pores. Are there
similar observations for AT1 receptor antagonists?
DR. ICHIKAWA: There are no data on AT1 in that regard.
DR. MADIAS: What do you think will be the long-term implica-
tions from the renal and systemic standpoints for patients with
renal disease treated with ACE inhibitors versus those treated
with AT1 antagonists?
DR. ICHIKAWA: We do not know. An interesting aspect of this
question is that when the pharmaceutical industry was developing
AT1 antagonists, they were simultaneously interested in develop-
ing antagonists that inhibit both AT1 and AT2 because they
feared that the activation of AT2 during AT1 inhibition alone
might do some harm. The function of AT2 is currently not entirely
understood. In some non-renal cells, such as smooth muscle cells
and mouse embryonic fibroblasts, which have only type-2 recep-
tor, AT2 mediated an apoptotic action of angiotensin [52].
DR. AJAY SINGH (Division of Nephrology, New England Medical
Center): You alluded to the angiotensin type-2 receptor knockout
mouse that has recently been developed. Could you describe the
phenotypic characteristics of this mouse? Further, using informa-
tion from this model, could you comment on the function of the
type-2 receptor?
DR. IcnIKAwA: AT2 is a unique blood-pressure-lowering sys-
tem. In normal rats, the AT2 antagonist induces natriuresis. Thus,
AT2 is salt retaining, yet blood pressure lowering. This is a very
unusual combination of phenotypes. Interestingly, AT2 appears
only in embryos. Embryos are in an anabolic state and need to
retain salt. The AT2 might allow embryos to retain salt, but
uniquely disallow the blood pressure to rise, which is highly
unfavorable for maternal-fetal circulatory dynamics.
In the embryonic kidney, AT2 appears around, not within, the
condensed, nephron-forming mesenchymal cells. The mesenchy-
ma! cells that did not participate in the formation of nephrons are
destined to disappear by apoptosis. AT2 might have some signif-
icant functions in embryos, and we hope that our ongoing studies
will shed light on them.
DR. KING: I'd like to follow up on the ACE gene polymorphism
you addressed. I was impressed by the protein-lowering effects in
the patients with IgA who had the DD allele. We know that the
anti-proteinuric effects of ACE inhibitors depend in large part on
sodium intake. Do you know whether these polymorphisms have
an impact on salt sensitivity?
DR. IcHIKAwA: We presented preliminary data on that issue
during the 1995 ASN meeting [53].
DR. KING: Getting back to the de Zeeuw paper from the
Netherlands, you implied that he observed a decrease in GFR
with ACE inhibitors. As I recall, that was a cross-over study,
finding essentially no change in GFR with either agent, and the
increase in renal blood flow was similiar.
DR. ICHIKAWA: In one study, the antiproteinuric effect corre-
lated very well with the preservation of serum creatinine [31]. Dr.
de Zeeuw also believes that the initial fall in GFR with ACE
inhibitors correlates well with the subsequent preservation of
GFR.
DR. KING: In the AT1 antagonist group, the reduction in
proteinuria was increased with the higher dosages despite no
further reduction in blood pressure. Would you like to speculate
on why that would be?
DR. ICHIKAWA: It is another complication that we often over-
look. The so-called hemodynamic effect might not necessarily be
transient and acute. As you know, once hypertension is estab-
lished, you cannot quickly normalize blood pressure by using a
converting enzyme inhibitor. If you give converting enzyme inhib-
itor from the beginning of the study, however, you can prevent the
blood pressure from rising. These somewhat conflicting phenom-
ena likely indicate that high blood pressure is caused not only by
vasoconstriction but by hypertrophy of vessels as well. I speculate
that it requires a long time and a higher dose of AT1 to normalize
microvascular hypertrophy within the kidney and to reduce gb-
merular pressure.
DR. HARRINGTON: You said that you could detect reversal of
sclerosis in animals treated with AT receptor antagonists. What
technique did you use to demonstrate reversal of sclerosis in an
individual glomerulus? What do you think accounts for the
reversal? Might angiogenesis factors be involved?
DR. IcHIKAwA: I saw at a conference held in Fuji, Japan, a
picture of revascularization of glomerular capillaries in animals
treated with a converting enzyme inhibitor. Our investigation was
not at that level of sophistication. Our study used ACE inhibitor
alone [25], and a study by Wayne Border's group used a combi-
nation of low-protein diet and ACE inhibitor [26]. We evaluated
glomeruloscierosis in terms of the percentage of glomerular tufts
that are occupied by the matrix and that have collapsed capillaries.
Converting enzyme inhibitors decreased this parameter. Usually
converting enzyme inhibitors are given at the time of 5/6 nephrec-
tomy. Only in such studies can their capacity to prevent deterio-
ration best be demonstrated. We instead waited eight weeks after
5/6 nephrectomy and then performed a renal biopsy. A few weeks
later, we evaluated the morphology within the same kidneys,
thereby simulating the situation in humans, that is, allowing
established structural changes to be reversed. With regard to your
last question, I know of no study attempting to identify specific
factors involved in the reversal.
DR. ANDREW S. LEVEY (Division of Nephrology, New England
Medical Center): Can you envision any therapeutic usefulness for
administering an ACE inhibitor and an angiotensin II type-i
receptor antagonist together?
DR. ICHIKAWA: I recall an abstract showing that the combination
does worse. One study showed that the glomerular pressure is very
high when both agents are given in rats. To answer your question,
I do not see any specific advantage of the combination.
DR. MADIA5: I'd like to expand on Dr. Singh's earlier question.
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Can you summarize for us the differences between ACE knockout
and the AT1 receptor knockout mice?
DR. ICHIKAWA: The ACE knockout mouse is phenotypically
comparable to the angiotensin knockout mouse; both have very
low blood pressure. There are additional, although unconfirmed,
differences in phenotype between male and female ACE knockout
mice. Unlike humans, rodents have two AT1 subtype receptors.
The homozygote of angiotensin knockout has only modestly low
blood pressure.
DR. KING: My question relates to the bradykinin data that you
presented. Edwards' data on this subject suggested that there was
considerable species variability in the effect of bradykinin on the
efferent arteriole [50]. Has anyone infused a bradykinin antagonist
into humans, and does that lead to an antiproteinuric effect?
DR. IcNIKAwA: I heard that HOE 140, a bradykinin antagonist,
was approved for human study early this year. Some data,
therefore, will be forthcoming.
DR. SINGH: Iwant to commend you on the terrific work with the
various knockout models. Could you expand on something you
said about knockout models, namely, that they sometimes uncover
paradoxical and antagonistic functions? Indeed, with regard to the
AT2 knockout model, you have made observations contrary to
what is commonly understood to be the function of this molecule.
Could you please put the value of data generated by knockout
models in some perspective for us?
DR. IcIJIKAwA: I list three caveats in interpreting data from
knockout mice: (1) Knockout experiments should not be regarded
as a gold standard for phenotype analysis. (2) There are some
unresolved issues in knockout studies because many of the
abnormal phenotypes in mutant mice might be secondary phe-
nomena. For example, an abnormality in one organ might sec-
ondarily cause a morphologic or functional defect in another
organ. We have three different techniques for getting around
these issues: one is tissue-specific knockout, another is gene-
rescuing technique, and the third is regional knockout. The last
creates both wild-type and knockout-type cells within the kidney,
so that both are under the same systemic milieu. (3) The currently
available data from knockout mice should be interpreted in
conjunction with other in-vivo and in-vitro data.
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